Ratings Evogene Ltd. Nasdaq

Equities

EVGN

IL0011050551

Market Closed - Nasdaq 16:30:00 2024-06-27 EDT 5-day change 1st Jan Change
0.691 USD +7.36% Intraday chart for Evogene Ltd. +12.34% -17.74%

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
-17.74% 31.83M - -
+21.85% 46.93B
B-
+37.63% 39.08B
A
-8.05% 38.48B
B
+29.04% 31.01B
B
-13.75% 26.14B
C
+10.65% 25.88B
B-
+38.43% 12.53B
C+
-6.92% 11.36B
B+
-12.29% 10.65B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes